6/23/20
Merck announced on June 12, 2020 that Gardasil® received FDA approval for the prevention of certain HPV-Related Head and Neck Cancers. This expanded indication is welcome news validating the important information that Gardasil 9® prevents infections from HPV types 16, 18, 31, 33, 45, 52, and 58 thus can also prevent oropharyngeal and other head and neck cancers related to these infections.